Skip to main content
Signal8

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Brainstorm Cell Therapeutics Inc. logo

Brainstorm Cell Therapeutics Inc.

OTC:BCLIHealthcare
-7.26%$0.8810
CLOSED
Mkt Cap$12.56M
EV-
Float11.42M
O/S14.26M
VOL83K sh
$ Vol$79K
RVOL3.75×
Inst Own-
SI0.5%
Net Cash/Sh-
Dilution
Brainstorm Cell Therapeutics Inc. logoOTC:BCLIClosed$0.8810-7.26%

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 32 SEC filings.

Shelf registration
S-3 filed Sep 17, 2024, effective Sep 27, 2024
Source: 10-Q filed Nov 16, 2026
At-the-market (ATM) program
Yes, sales agreement dated Aug 9, 2021
Source: 10-Q filed Nov 16, 2026
Warrants outstanding
7 warrant series recorded as outstanding
Most recent offering
PIPE, closed Oct 27, 2026
Source: 10-Q filed Nov 16, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro